Nancy Martin Email and Phone Number
Nancy Martin work email
- Valid
- Valid
- Valid
Nancy Martin personal email
Dr. Nancy Martin is an experienced pharmaceutical R&D executive with over 25 years of value-added impact to patients. She is a strategic leader and independent thinker with a flexible approach to deliver results. She has broad and deep experience in clinical practice and the pharmaceutical industry. Nancy is regarded as a trusted advisor to multidisciplinary teams in dynamic environments in small, mid-size and large organizations. Having worked in a multitude of therapeutic areas in various roles across disciplines including clinical pharmacology & biopharmaceutics, preclinical development, clinical development, medical science and medical affairs in all phases of drug and/or device development, Nancy is driven by the promise of bring new therapies to patients. Nancy has lead teams through strategic negotiations with various health authorities including numerous successful global submissions, product defenses, successful FDA Advisory Committees/ EU Oral Explanations and first-cycle approvals of new drugs, biologics, generics, biosimilars, devices, and combination products. She is currently leading her team at Astellas to advance cellular and gene therapies as part of the diversified portfolio of transformative therapeutics across medical specialties. She is a catalyst for cross-functional teams in their strategic delivery to key milestones for high profile development portfolio decisions. Nancy is trained as a physician and pharmacist. Her career began as a clinical pharmacologist at Hoffmann-La Roche. Throughout her career, Nancy held roles of increasing responsibility at Roche, Aventis, Hospira, Pfizer, Baxter and Astellas across multiple disciplines in research, development and medical affairs. She served as Chief Medical Officer of Outpost Medicine, a Frazier Portfolio Company with focus in women’s health and as Chief Medical Officer of TerSera Therapeutics, a GTCR Portfolio Company, with focus in oncology and rare disease.Nancy is a keen advocate of professional development for team members as an invested people manager. In addition, Nancy maintains connections as Adjunct Faculty for her alma maters and mentors pharmacy and medicine fellows with career interest in the pharmaceutical industry. Nancy is an author of over 100 scientific abstracts, posters, manuscripts and book chapters and has been an invited speaker at numerous international scientific congresses. She maintains active licenses as a registered pharmacist and as a physician to practice medicine in multiple jurisdictions.
Bluechain Bio
View- Website:
- bluechainbiotx.com
- Employees:
- 3
-
Co-Founder, Chief Medical OfficerBluechain BioChicago, Il, Us -
Managing DirectorClinically Meaningful, Llc Jul 2016 - PresentClinically meaningful started out in 2017, where I provided consultation services to Pfizer including a successful delivery of a positive FDA Oncologic Drugs Advisory Committee Vote for the first US Epoetin Biosimilar (May 25, 2017). Served as the primary presenter and defended the nonclinical and clinical data package in support of a positive benefit/risk assessment at the FDA ODAC for Retacrit (epoetin biosimilar). In 2024, my consultation services are again available to companies in support of efficient solutions to a broad range of pharmaceutical product development and health authority engagement needs.
-
Chief Medical Officer, Executive Vice President R&DTersera Therapeutics May 2022 - Aug 2024Deerfield, Illinois, UsReporting to the Chief Executive Officer, I served in an executive leadership capacity as a management partner leading the strategic and operational excellence of the medical affairs, clinical development, pharmacovigilance and regulatory affairs disciplines of TerSera Therapeutics. -
Vice President, Global Medical Science Head, Medical SpecialtiesAstellas Pharma Jul 2019 - May 2022Reporting to the Senior Vice President, Development Therapeutic Areas, I serve in an executive leadership capacity to drive medical strategic direction for the medical team in Medical Specialties, Medical & Development. In this role, I am responsible for overseeing the design and delivery of the medical strategic elements of development programs across a variety of primary focus areas and platform modalities. My role is accountable to ensure that medical expertise and scientific excellence is incorporated into holistic evidence generation plans from preclinical candidate nomination through all phases of clinical development across a multitude of therapeutic areas including rare diseases with the promise of advancing transformative medicines to patients. As a leader through leaders, my role is to strategically coach, mentor and facilitate the success of the medical directors on my global team. In this capacity, I also lead integration efforts of new inorganic growth in Astellas including the integration of cell therapies (AIRM) and gene therapies (AGT) development portfolios as part of the broader development organization. In addition, I drive strategic medical leadership in the evaluation of potential acquisition targets through risk-mitigating diligence contributions, ensuring high quality and timely medical review of in-licensing opportunities, out-licensing and/or multi-track activities. -
Vice President, Clinical And Preclinical DevelopmentBaxter International Inc. Oct 2017 - May 2019Deerfield, Illinois, UsReporting to the Chief Science and Technology Officer and member of the R&D senior leadership team, I served in an executive capacity to lead a transformation of the clinical and preclinical R&D organization, optimizing development strategy and operational excellence culminating in $10 million savings for the organization while enhancing scientific rigor, development acumen and R&D governance. In this role, I lead a global team of >150 colleagues in clinical and preclinical development including the disciplines of clinical strategy, global clinical operations, data sciences, medical writing, preclinical model development, regulatory toxicology and biocompatibility sciences. I was accountable to the CSO, CEO and Management Committee for growth through innovation with a highly diversified portfolio of drug, drug/device combination and device assets across six global business units including overall product development strategy, oversight of evidence generation plans, clinical and preclinical development technical expertise, and delivery of programs on budget and plan. -
Senior Vice President, Chief Medical Officer, Outpost Medicine, A Frazier Portfolio CompanyFrazier Healthcare Partners Jul 2016 - Oct 2017Seattle, Wa, UsReporting directly to the Chief Executive Officer, I served in an executive capacity leading a global clinical, regulatory, quality and medical affairs organization with focus on women's heath in genitourinary and gastrointestinal conditions. In this role as CMO of a Frazier Portfolio Company, I was accountable to the CEO and Board of Directors for value creation with a portfolio of assets including overall development strategy, clinical, regulatory and quality expertise, oversight of development plans, an delivery of development programs on budget and plan while maintaining key opinion leader relationships for ongoing medical affairs activities. -
Vice President, Clinical Development BiosimilarsPfizer May 2015 - Jul 2016New York, New York, UsReporting directly to the Chief Medical Officer, Global Established Products R&D and member of the CMO leadership team, I lead a clinical development organization with focus o the biosimilars portfolio. In this role, I was accountable for a portfolio of multiple biosimilar assets for development strategy, clinical expertise, oversight of clinical development plans and deliverly of clinical programs on budget and plan. I was responsible for advancing key decisions collaboratively with multiple functional lines (commercial, clinical operations, safety, regulatory, pharmaceutical sciences, medical affairs, QA, legal) in the biosimilars franchise. My role included coaching and mentoring physicians and allied health care professional clinical staff. Governance appointments included: Chair of the GDP technical review committee, core member of the GEP R&D executive strategy committee, core member of the R&D biosimiars portfolio segment team, member of the Pfizer Global Clinical Leadership Team, and Member of the CMO Leadership Team. -
Vice President, Global Clinical Development, Hospira, A Pfizer CompanyPfizer May 2013 - May 2015New York, New York, UsAs Vice President, Global Clinical Development at Hospira, A Pfizer Company, I reported directly to the Chief Medical Officer and lead a global cross function clinical development organization comprise of medical development, clinical pharmacology, statistics, data management, and clinical programming supporting all phases of development and life cycle management. In this role, I build the in house capability/ bench strength with a lean resourcing model to drive clinical, clinical pharmacology and data sciences deliverables for multiple INDs, sNDAs, MAAs, 351(k) BLAs and biosimilar MAAs. The scope of this portfolio included proprietary innovative drug products, specialty injectable generic products and biosimilars. Hospira was acquired by Pfizer in 2015 where I served as the R&D integration leader in the M&A activities where I successfully found placement for the 1500 R&D colleagues at Hospira in the broader Pfizer organization. -
Senior Medical Director, Astellas Scientific And Medical AffairsAstellas Pharma Jan 2012 - May 2013In this role, I lead the Urology Astellas Scientific and Medical Affairs team to ensure launch excellence for Myrbetriq/Betmiga, a first in class, novel therapeutic for overactive bladder. I was accountable for the medical affairs strategic plan for product approval and launch preparation activities for Myrbetriq (mirabegron) and ongoing medical affairs leadership for VESIcare (solifenacin). I co-lead with my commercial colleagues the design of the strategic plan for the global urology franchise. In this role, I ensured key partnerships for product support with internal and external stakeholders for LCM planning and execution, publication support, lead medical support for regulatory inquiries, and provided medical oversight to Phase 3b/4 trials as well as IIS activities. -
Medical Director, Medical SciencesAstellas Pharma Oct 2009 - Dec 2012I served as Global Medical Lead for Myrbetriq/Betmiga where I was accountable for the medical strategy and delivery of the mirabegron development program to support global registrations, defenses and approvals. In this role, I provided medical leadership to the team which achieved simultaneous submissions in advance of goal for the EU-MAA and US-NDA in August 2011. The product obtained first cycle approval in various regions submitted with successful negotiations with multiple health authorities (FDA/EMA/PMDA/HC/TGA). The product enjoys its successful approval in over 81 countries and successful launch across the regions. -
Associate Medical Director, Medical SciencesAstellas Pharma Oct 2008 - Oct 2009I provided medical leadership for the global Phase 2/3 development program for mirabegron in overactive bladder, delivering a 41 study global clinical development package. I also served as medical lead for various GI programs in Phase 2 development in this role. -
Clinical Pharmacokineticist, Global Biopharmaceutics At Aventis, IncSanofi Aug 2000 - Aug 2003Paris, France, FrIn this role, I was responsible for driving DMPK interdepartmental drug development programs (Ph 1-3) for new chemical entities (M100240, carioride, exubera) through the use of multidisciplinary matrix teams. I was responsible for the development and implementation of clinical pharmacology programs in support of NDA/MAA submissions including strategy and clinical trial execution. -
Clinical PharmacologistRoche Jul 1997 - Jul 2000Switzerland 🇨🇭 , ChIn this role, I implemented the clinical pharmacology/clinical pharmacokinetic program including authorship of the clinical pharmacology sections of the NDA/MAA submission for PEGASYS (pegylated interferon alfa-2a). I served as the lead clinical pharmacologist for product labeling for this product. In addition, I was a major contributor to the clinical pharmacology dossier for the global NDA/MAA submissions for Tamiflu (olseltamivir phosphate) with a significant role in conducting the 22 clinical pharmacology studies in support of a rapid EIH to NDA submission in 2.4 years. Additional program support included clinical pharmacology characterization of an endothelin antagonist, Zenapax and Lenercept.
Nancy Martin Education Details
-
Rutgers Robert Wood Johnson Medical SchoolDoctor Of Medicine - Md -
University Of Illinois ChicagoDoctor Of Pharmacy - Pharmd -
Northwestern University - The Feinberg School Of MedicineResidency In Ophthalmology -
Cornell UniversityInternal Medicine -
Rutgers UniversityPost Doctoral Fellowship In Clinical Pharmacology -
University Of Missouri-Kansas CityPre-Pharmacy Curriculum
Frequently Asked Questions about Nancy Martin
What company does Nancy Martin work for?
Nancy Martin works for Bluechain Bio
What is Nancy Martin's role at the current company?
Nancy Martin's current role is Co-Founder, Chief Medical Officer.
What is Nancy Martin's email address?
Nancy Martin's email address is na****@****llas.us
What schools did Nancy Martin attend?
Nancy Martin attended Rutgers Robert Wood Johnson Medical School, University Of Illinois Chicago, Northwestern University - The Feinberg School Of Medicine, Cornell University, Rutgers University, University Of Missouri-Kansas City.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial